Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for Neoadjuvant Therapies in MIBC
NCT06341478Recruiting
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Open-label trial of sacituzumab govitecan, pembrolizumab, nivolumab and paclitaxel in muscle-invasive bladder cancer (MIBC) (4 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Predictors of immune response to experimental combination therapies in MIBC, Genomic predictors of response to experimental combination therapies in MIBC and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06341478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341478.